American Mothers Say No to China's Vape Dumping Ground. The FDA Has Authorized Six. There Are Thousands on the Shelves.

Emily Stack's headline framing is precise: dumping ground. In international-trade law, dumping describes the practice of exporting a product at a price below the home-market price or below cost. China-domestic policy as of 2022 banned the sale of fruit-flavored and candy-flavored disposable vapes to Chinese consumers. The Chinese vape industry continues to manufacture exactly those flavors — mango ice, rainbow candy, bubblegum, grape slushie — and exports them to the United States, where FDA enforcement has been thin enough that they reach convenience stores and bodegas at scale.

“American families are being treated like a dumping ground for products the Chinese government does not want widely sold to its own people.”

Emily Stack, Executive Director, Moms for America Action · Washington Examiner, May 20, 2026

That asymmetry — banned at home, exported at scale to US teens — is the core of the Stack-Moms-for-America campaign. The campaign's policy fix, as Stack articulated it in the op-ed: any product authorized for sale in the US should require final manufacturing in an FDA-inspected U.S. facility. That would functionally end the flow of unregulated Chinese disposables overnight, since none are made in FDA-inspected US facilities.

On May 14, 2026, CBP, USCG, and FDA executed Operation Red Mist. The official CBP press release detail: 18 million illegal disposable vape units, $175 million street value, shipments “contained hazardous materials misclassified and improperly labeled” to evade customs detection.

Operation Red Mist was the largest single coordinated federal action against Chinese disposables to date — but it followed the September 25, 2025 DEA Operation Vape Trail, which seized 4.7 million units with $86.5 million street value in Chicago alone, plus a separate May 2025 FDA/ICE action that took $34 million in Chinese disposables out of distribution.

The legislative response in the 119th Congress has been bipartisan but slow. Sen. Tom Cotton (R-AR) introduced the ENDS Chinese Vapes Act (S.4303) in early 2026 — explicit statutory authority to interdict, seize, and prosecute the import of Chinese disposables not authorized by the FDA.

On the Democratic side, Sen. Dick Durbin (D-IL) grilled HHS Secretary RFK Jr.in a Senate Appropriations hearing on the FDA's historical failure to enforce the deeming-rule premarket-authorization regime against Chinese disposables. Sen. Marco Rubio (R-FL) sent a separate letter to the FDA: “The FDA is blowing smoke when it comes to Chinese vapes.” House Oversight sought a DOJ briefing.

“The FDA is blowing smoke when it comes to Chinese vapes.”

Sen. Marco Rubio (R-FL), letter to FDA, 2026

Two weeks before Stack's Washington Examiner op-ed, on May 6, 2026, the FDA approved a new tranche of flavored vapes — a decision STAT News documented as controversial and potentially politically influenced. The approval split the anti-vape coalition: PAVe (Parents Against Vaping E-cigarettes), the Campaign for Tobacco-Free Kids, and Truth Initiative criticized the approval as a move that opened the regulatory door to more flavored products. Moms for America Action's response was the campaign launch and the Stack op-ed.

FDA Commissioner Marty Makary, M.D., M.P.H. (R) is reported to have departed; Kyle Diamantas is acting commissioner. The departure timing — coincident with the May 6 approval and the May 14 Operation Red Mist seizure — suggests internal FDA tension over enforcement direction.

Three accountable parties:

• The FDA— ten years of paralysis since the 2016 deeming rule. Only ~6 unique authorizations. A May 6, 2026 flavor-vape approval that split the anti-vape coalition. Makary out; Diamantas acting.
• Beijing— bans the flavored disposables at home, manufactures them at industrial scale for export, and ships them to the United States where teens consume them. The asymmetry is policy, not accident.
• Congress— the Cotton ENDS Chinese Vapes Act has not passed. The Durbin / Rubio pressure has not forced agency action. The $200 million FY26 FDA enforcement appropriation has not closed the gap.